160 related articles for article (PubMed ID: 30466410)
1. Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review.
Rochigneux P; Thomassin-Piana J; Laibe S; Brunelle S; Salem N; Escudier B; Vassal G; Gravis G
BMC Cancer; 2018 Nov; 18(1):1159. PubMed ID: 30466410
[TBL] [Abstract][Full Text] [Related]
2. The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Schuller AG; Barry ER; Jones RD; Henry RE; Frigault MM; Beran G; Linsenmayer D; Hattersley M; Smith A; Wilson J; Cairo S; Déas O; Nicolle D; Adam A; Zinda M; Reimer C; Fawell SE; Clark EA; D'Cruz CM
Clin Cancer Res; 2015 Jun; 21(12):2811-9. PubMed ID: 25779944
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy in Xp11 translocation renal cell carcinoma.
Gomolčáková J; Brezinová B; Dubovan P; Jurišová S; Rejlekova K; Chovanec M; Mardiak J; Mego M
Klin Onkol; 2021; 34(2):137-140. PubMed ID: 33906362
[TBL] [Abstract][Full Text] [Related]
5. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Pal SK; Tangen C; Thompson IM; Balzer-Haas N; George DJ; Heng DYC; Shuch B; Stein M; Tretiakova M; Humphrey P; Adeniran A; Narayan V; Bjarnason GA; Vaishampayan U; Alva A; Zhang T; Cole S; Plets M; Wright J; Lara PN
Lancet; 2021 Feb; 397(10275):695-703. PubMed ID: 33592176
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
Choueiri TK; Heng DYC; Lee JL; Cancel M; Verheijen RB; Mellemgaard A; Ottesen LH; Frigault MM; L'Hernault A; Szijgyarto Z; Signoretti S; Albiges L
JAMA Oncol; 2020 Aug; 6(8):1247-1255. PubMed ID: 32469384
[TBL] [Abstract][Full Text] [Related]
7. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.
Stein MN; Hirshfield KM; Zhong H; Singer EA; Ali SM; Ganesan S
Eur Urol; 2015 Feb; 67(2):353-4. PubMed ID: 25457019
[No Abstract] [Full Text] [Related]
8. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Jorge SE; Schulman S; Freed JA; VanderLaan PA; Rangachari D; Kobayashi SS; Huberman MS; Costa DB
Lung Cancer; 2015 Dec; 90(3):369-74. PubMed ID: 26791794
[TBL] [Abstract][Full Text] [Related]
9. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
Courthod G; Tucci M; Di Maio M; Scagliotti GV
Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
[TBL] [Abstract][Full Text] [Related]
10. De Novo MET Amplification in Chinese Patients With Non-Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study.
Song Z; Wang H; Yu Z; Lu P; Xu C; Chen G; Zhang Y
Clin Lung Cancer; 2019 Mar; 20(2):e171-e176. PubMed ID: 30554986
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
12. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.
Ciamporcero E; Miles KM; Adelaiye R; Ramakrishnan S; Shen L; Ku S; Pizzimenti S; Sennino B; Barrera G; Pili R
Mol Cancer Ther; 2015 Jan; 14(1):101-10. PubMed ID: 25381264
[TBL] [Abstract][Full Text] [Related]
13. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.
Denize T; Just PA; Sibony M; Blons H; Timsit MO; Drossart T; Jakubowicz D; Broudin C; Morini A; Molina T; Vano Y; Auvray-Kuentz M; Richard S; Mejean A; Gimenez Roqueplo AP; Burnichon N; Verkarre V
Mod Pathol; 2021 Mar; 34(3):647-659. PubMed ID: 32770124
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
Moro-Sibilot D; Cozic N; Pérol M; Mazières J; Otto J; Souquet PJ; Bahleda R; Wislez M; Zalcman G; Guibert SD; Barlési F; Mennecier B; Monnet I; Sabatier R; Bota S; Dubos C; Verriele V; Haddad V; Ferretti G; Cortot A; De Fraipont F; Jimenez M; Hoog-Labouret N; Vassal G
Ann Oncol; 2019 Dec; 30(12):1985-1991. PubMed ID: 31584608
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib in
Landi L; Chiari R; Tiseo M; D'Incà F; Dazzi C; Chella A; Delmonte A; Bonanno L; Giannarelli D; Cortinovis DL; de Marinis F; Borra G; Morabito A; Gridelli C; Galetta D; Barbieri F; Grossi F; Capelletto E; Minuti G; Mazzoni F; Verusio C; Bria E; Alì G; Bruno R; Proietti A; Fontanini G; Crinò L; Cappuzzo F
Clin Cancer Res; 2019 Dec; 25(24):7312-7319. PubMed ID: 31416808
[TBL] [Abstract][Full Text] [Related]
17. [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
Rabeau A; Rouquette I; Vantelon JM; Taranchon-Clermont E; Mazières J
Rev Mal Respir; 2017 Jan; 34(1):57-60. PubMed ID: 27745897
[TBL] [Abstract][Full Text] [Related]
18. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Choueiri TK; Plimack E; Arkenau HT; Jonasch E; Heng DYC; Powles T; Frigault MM; Clark EA; Handzel AA; Gardner H; Morgan S; Albiges L; Pal SK
J Clin Oncol; 2017 Sep; 35(26):2993-3001. PubMed ID: 28644771
[TBL] [Abstract][Full Text] [Related]
19. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
Chen Q; Cheng L; Li Q
Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
[No Abstract] [Full Text] [Related]
20. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
